Signal

$INCY

- Incyte reported Q1 2026 total revenue of $1.27B (up 21% YoY) and net sales of $1.10B (up 20%), driven by Jakafi ($758M, +7%), Opzelura ($143M, +20%), and hematology/oncology portfolio ($204M, +116%)

INCY

$113.75

+5.78%

What changed

$INCY - Incyte reported Q1 2026 total revenue of $1.27B (up 21% YoY) and net sales of $1.10B (up 20%), driven by Jakafi ($758M, +7%), Opzelura ($143M, +20%), and hematology/oncology portfolio ($204M, +116%); the company highlighted four anticipated approvals/launches from mid-2026 into early 2027, NDA acceptance for povorcitinib in HS, positive Phase 3 results in vitil

Why it matters

Sources

pipeline